Search Results

The triggering pathway, the metabolic amplifying pathway, and cellular transduction in regulation of glucose-dependent biphasic insulin secretion.

• Authors : Bisht S; Amity Institute of Pharmacy, Amity University, Lucknow, Uttar Pradesh, India.; Singh MF

Subjects: Insulin Secretion*/Insulin Secretion*/Insulin Secretion*/drug effects ; Glucose*/Glucose*/Glucose*/metabolism ; Insulin-Secreting Cells*/Insulin-Secreting Cells*/Insulin-Secreting Cells*/metabolism

• Source: Archives of physiology and biochemistry [Arch Physiol Biochem] 2024 Dec; Vol. 130 (6), pp. 854-865. Date of Electronic Publication: 2024 Jan 09.Publisher: Informa Healthcare Country of Publication: England NLM ID: 9510153 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Real-world study of the concomitant use of biphasic insulin aspart 30/70 with GLP-1 receptor agonist versus first-generation basal insulin with GLP-1 receptor agonist in type 2 diabetes.

• Authors : Davies M; Diabetes Research Centre, College of Life Sciences, University of Leicester, Leicester General Hospital, Leicester, UK.; NIHR Leicester Biomedical Research Centre, Leicester General Hospital, Leicester, UK.

Subjects: Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy ; Hypoglycemia*/Hypoglycemia*/Hypoglycemia*/drug therapy; Humans

• Source: Diabetic medicine : a journal of the British Diabetic Association [Diabet Med] 2024 May; Vol. 41 (5), pp. e15267. Date of Electronic Publication: 2023 Dec 13.Publisher: Blackwell Science Country of Publication: England NLM ID: 8500858 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Efficacy and Safety of Insulin Degludec/Insulin Aspart versus Biphasic Insulin Aspart 30 in Patients with Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials.

• Authors : Niu YL; Endocrinology Department, Luodian Hospital, Baoshan District of Shanghai, Shanghai, China.; Zhang Y

• Source: Iranian journal of public health [Iran J Public Health] 2024 Feb; Vol. 53 (2), pp. 313-322.Publisher: Anjuman-i Bihdāsht-i Īrān Country of Publication: Iran NLM ID: 7505531 Publication Model: Print Cited Medium: Internet ISSN:

Record details

Functionally heterogeneous β cells regulate biphasic insulin secretion.

• Source: Nature metabolism [Nat Metab] 2024 Feb; Vol. 6 (2), pp. 207-208.Publisher: Springer Nature Country of Publication: Germany NLM ID: 101736592 Publication Model: Print Cited Medium: Internet ISSN: 2522-5812

Record details

China Clinical Trial: The First Affiliated Hospital of Dalian Medical University Registers Clinical Trial to Study Subcutaneous Injection Of Biphasic Insulin Aspart 30 with Needle Free Syringe and Insulin Pen on Insulin Usage in Patients with Type 2 Diabetes.

• Source: Contify Life Science News. 2024.

Record details

Glycaemic control and weight outcomes after adding or switching to biphasic insulin aspart 30/70 in people with type 2 diabetes mellitus previously treated with basal-bolus insulin in UK clinical practice.

• Authors : Davies MJ; Diabetes Research Centre, College of Life Sciences, University of Leicester, Leicester General Hospital, Leicester, UK.; NIHR Leicester Biomedical Research Centre, Leicester General Hospital, Leicester, UK.

• Source: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2023 Dec; Vol. 25 (12), pp. 3841-3844. Date of Electronic Publication: 2023 Sep 18.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Bioequivalence of Reference and Biosimilar Preparations of Premixed Biphasic Insulin Aspart: A Comparative Clamp Study.

• Authors : Dorotenko A; R&D Center, GEROPHARM, Saint-Petersburg, Russia.; Makarenko I

Subjects: Biphasic Insulins* ; Biosimilar Pharmaceuticals*/Biosimilar Pharmaceuticals*/Biosimilar Pharmaceuticals*/adverse effects; Male

• Source: Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2023 Dec; Vol. 12 (12), pp. 1178-1184. Date of Electronic Publication: 2023 Sep 20.Publisher: Wiley Country of Publication: United States NLM ID: 101572899 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Real-world study of ethnic differences in glycaemic control and clinical characteristics among insulin-naïve people with type 2 diabetes initiating biphasic insulin aspart 30/70: A retrospective, observational cohort study in England.

• Authors : Davies MJ; Diabetes Research Centre, College of Life Sciences, Leicester General Hospital, University of Leicester, Leicester, UK.; NIHR Leicester Biomedical Research Centre, Leicester General Hospital, Leicester, UK.

Subjects: Insulin*/Insulin*/Insulin*/therapeutic use ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/epidemiology

• Source: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2023 Sep; Vol. 25 (9), pp. 2756-2764. Date of Electronic Publication: 2023 Jun 19.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Reports Summarize Type 2 Diabetes Findings from Emergency Department (Efficacy and Safety of Insulin Degludec/insulin Aspart Versus Biphasic Insulin Aspart 30 In Patients With Type 2 Diabetes: a Meta-analysis of Randomized Controlled Trials)

• Source: Health & Medicine Week. April 26, 2024, 269

Record details

New Antidiabetic Agents Study Results Reported from R&D Center (Pkpd Modeling and Simulations To Support Biosimilar Development of Biphasic Insulin Aspart 30)

• Source: Obesity, Fitness & Wellness Week. September 17, 2022, 2850

Record details